Epidrugs: Toward Understanding and Treating Diverse Diseases

Message from the Guest Editor

Dear Colleagues,

Epigenomic modifications are unique in that the type and amount of chemical modification at each chromosomal location can vary from cell to cell. In recent years, not only have these epigenomic modifications been revealed genome-wide, but rapid progress has also been made in the identification of the proteins responsible for epigenomic modifications and the development of their regulatory compounds. This Special Issue on "Epidrugs" aims to provide insights into broad aspects of biology and drug development through epigenome-regulating compounds.
Message from the Editor-in-Chief

In the past years the growth of the epigenetic field has been outstanding, from here the need of a journal where to centralize all new information on the subject. The term epigenetics is now broadly used to indicate changes in gene functions that do not depend on changes in the sequence of DNA. *Epigenomes* covers all areas of DNA modification from single cell level to multicellular organism as well as the epigenetics on human pathologies and behavior.

*Epigenomes* (ISSN 2075-4655) is a fully peer-reviewed publication outlet with a rapid and economical route to open access publication. All articles are peer-reviewed and the editorial focus is on determining that the work is scientifically sound rather than trying to predict its future impact.

Author Benefits

**Open Access:**— free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, ESCI (Web of Science), PMC, PubMed, PubAg, CAPlus / SciFinder, and other databases.

**Journal Rank:** CiteScore - Q2 (*Biochemistry, Genetics and Molecular Biology (miscellaneous)*)

Contact Us

*Epigenomes*
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

tel: +41 61 683 77 34
www.mdpi.com
epigenomes@mdpi.com
@Epigenomes